MX341202B - Composiciones de plasma rico en plaquetas. - Google Patents

Composiciones de plasma rico en plaquetas.

Info

Publication number
MX341202B
MX341202B MX2013001842A MX2013001842A MX341202B MX 341202 B MX341202 B MX 341202B MX 2013001842 A MX2013001842 A MX 2013001842A MX 2013001842 A MX2013001842 A MX 2013001842A MX 341202 B MX341202 B MX 341202B
Authority
MX
Mexico
Prior art keywords
rich plasma
platelet
plasma compositions
relates
compositions
Prior art date
Application number
MX2013001842A
Other languages
English (en)
Other versions
MX2013001842A (es
Inventor
Agut Sánchez Julian
Fernández Navarro Carlos
Cos Trulllas Joan
Ocaña Safont Laura
Genove Corominas Elsa
Original Assignee
Opko Lab Europe S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Lab Europe S L filed Critical Opko Lab Europe S L
Publication of MX2013001842A publication Critical patent/MX2013001842A/es
Publication of MX341202B publication Critical patent/MX341202B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición para administración oral que comprende plasma rico en plaquetas de origen heterólogo para su uso en el tratamiento o la prevención de la discapacidad funcional y/o del dolor asociado cori lesiones, trastornos o enfermedades del tejido conjuntivo, de los tendones o de las articulaciones. . La invención también se refiere a composiciones farmacéuticas y a composiciones nutricionales administradas por vía oral que comprenden plasma rico en plaquetas heterólogo y a usos de las mismas.
MX2013001842A 2012-02-17 2013-02-15 Composiciones de plasma rico en plaquetas. MX341202B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12155924.9A EP2628484B9 (en) 2012-02-17 2012-02-17 Platelet-rich plasma compositions

Publications (2)

Publication Number Publication Date
MX2013001842A MX2013001842A (es) 2013-08-27
MX341202B true MX341202B (es) 2016-08-09

Family

ID=45656027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001842A MX341202B (es) 2012-02-17 2013-02-15 Composiciones de plasma rico en plaquetas.

Country Status (13)

Country Link
US (1) US9233126B2 (es)
EP (1) EP2628484B9 (es)
BR (1) BR102013003570A8 (es)
CL (1) CL2013000426A1 (es)
CO (1) CO7030201A1 (es)
DK (1) DK2628484T3 (es)
ES (1) ES2579857T3 (es)
HR (1) HRP20160719T1 (es)
HU (1) HUE030322T2 (es)
MX (1) MX341202B (es)
PL (1) PL2628484T3 (es)
RS (1) RS54845B1 (es)
SI (1) SI2628484T1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1194912A2 (en) * 2013-09-17 2014-10-24 Bestop Group Holdings Ltd Growth factor concentrate and the use thereof
CN105030645A (zh) * 2015-09-14 2015-11-11 广州赛莱拉干细胞科技股份有限公司 一种组合物及其制备方法、美容制剂
WO2017082441A1 (ko) * 2015-11-13 2017-05-18 중부대학교 산학협력단 활성화된 혈소판 풍부 혈장을 유효성분으로 포함하는 동물의 창상 치료용 수의학적 조성물
RU2618649C1 (ru) * 2015-12-02 2017-05-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) Способ хирургического лечения осложненной язвы двенадцатиперстной кишки
EP3487520A1 (en) 2016-07-21 2019-05-29 Khorakiwala, Habil F Topical pharmaceutical composition for promoting hair growth and/or reducing hair loss
RU2644934C1 (ru) * 2016-12-29 2018-02-14 Руслан Расулжанович Шеров Способ эндоскопического лечения гастродуоденальных язв
US10624615B2 (en) 2017-10-06 2020-04-21 Stephen S Ho Apparatus and method for collecting and isolating cells
CN107929711B (zh) * 2017-12-01 2021-08-31 福建蓝昊肽生物科技发展有限公司 一种血源酶解肽在制备抑制动物肠道炎症药物中的应用
JP7175055B1 (ja) 2021-05-14 2022-11-18 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法
CN114272359B (zh) * 2021-12-21 2024-06-18 青岛恩普生物技术有限公司 一种重组人血小板衍生生长因子pdgf治疗急性伤害性疼痛的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599558A (en) 1989-09-15 1997-02-04 Curative Technologies, Inc. Selecting amounts of platelet releasate for efficacious treatment of tissue
US5585007A (en) 1994-12-07 1996-12-17 Plasmaseal Corporation Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant
US5614204A (en) 1995-01-23 1997-03-25 The Regents Of The University Of California Angiographic vascular occlusion agents and a method for hemostatic occlusion
US6322785B1 (en) 1999-03-02 2001-11-27 Natrex Technologies Methods and compositions for bone graft implants
US6811777B2 (en) 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US20050191286A1 (en) * 2004-02-09 2005-09-01 Gandy James B. Lyophilized platelet rich plasma for the use in wound healing (chronic or acute) and bone or tissue grafts or repair
US20060159663A1 (en) * 2004-07-30 2006-07-20 Lu Helen H Growth factor encapsulation system for enhancing bone formation
US20060035383A1 (en) * 2004-08-12 2006-02-16 David Ho Dry platelet preparations for use in diagnostics
US7744895B2 (en) * 2005-08-31 2010-06-29 Yamanashi University Methods of treating allergies using TGF-β1 and allergens
ES2333498B1 (es) * 2007-08-02 2011-01-10 Biotechnology Institute, I Mas D, S.L. Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros, y el metodo de preparacion del compuesto.
WO2010005557A2 (en) * 2008-07-07 2010-01-14 Arteriocyte Medical Systems, Inc. Biological therapeutic compositions and methods thereof
EP2373321B1 (en) * 2008-12-05 2016-03-16 Biomed Device S.r.l. Platelet lysate and bioadesive compositions thereof for the treatment of mucositis
WO2011127071A1 (en) 2010-04-05 2011-10-13 Allan Mishra Platelet rich plasma formulations
US9168281B2 (en) * 2011-03-09 2015-10-27 Charles E. Worden, SR. Kit for treating a wound

Also Published As

Publication number Publication date
US20130216626A1 (en) 2013-08-22
US9233126B2 (en) 2016-01-12
CO7030201A1 (es) 2014-08-21
EP2628484B1 (en) 2016-04-20
SI2628484T1 (sl) 2016-07-29
PL2628484T3 (pl) 2016-10-31
EP2628484B9 (en) 2016-08-17
CL2013000426A1 (es) 2014-02-14
ES2579857T3 (es) 2016-08-17
RS54845B1 (sr) 2016-10-31
BR102013003570A2 (pt) 2013-12-17
HRP20160719T1 (hr) 2016-09-23
MX2013001842A (es) 2013-08-27
EP2628484A1 (en) 2013-08-21
HUE030322T2 (en) 2017-05-29
DK2628484T3 (en) 2016-08-01
BR102013003570A8 (pt) 2017-03-21

Similar Documents

Publication Publication Date Title
MX2013001842A (es) Composiciones de plasma rico en plaquetas.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
WO2012125007A3 (en) Methods and compositions for the treatment, prevention, and alleviation of bone and cartilage diseases or injuries and hair loss
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2016007955A (es) Pirrol carboxamidas iii fluorometil-sustituidas.
IN2014DN09240A (es)
MX2016013451A (es) Heterociclilsulfonas arilo sustituidas.
WO2013038200A3 (en) Neurodevelopmental disorders
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SUN BAY S.R.L. DE C.V.

FG Grant or registration